SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

Sanofi confirmed its full-year sales target for Dupixent of roughly 13 billion euros. Elsewhere, new pharma launches grew 67.1% to 727 million euros ($787), with hemophilia med Altuviiio ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia drug ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma launches increased 67.1% to 727 million euros, led by Altuviiio (hemophilia drug), Nexviazyme ...

With sales of a EUR172 million ALTUVIIIO further established its position ... This transaction marks an important strategic step for Sanofi to become a pure-play and science-focused biopharma ...

Sanofi (NASDAQ:SNY) Q3 2024 Earnings Call Transcript ... With sales of a EUR172 million ALTUVIIIO further established its ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant®, Vonjo® and Zynlonta®, and royalty on Sanofi's sales of Altuviiio® and Beyfortus. Investors ...